Abstract
Although in a gross sense fibrin is merely a collection of fibrinogen molecules packed together in bundles, numerous small structural differences can arise as a result of the conversion of the soluble precursor into the gelled product. Some of the consequences are obvious, others more subtle. In one way or another, all these changes are the result of a sequence of events that includes the release of the fibrinopeptides A and B, the formation of protofibrils, the cross-linking of γ chains, the assembly into mature fibers and the cross-linking of α chains. Numerous immunologic differences between fibrinogen and fibrin have been cataloged, and putative sites for fibrin enhancing the activity of plasminogen activators have been identified. Although some conformational changes have been found by X-ray crystallography, the structural changes leading to the exposure of sites thought to bind t-PA and/or plasminogen remain to be demonstrated.
Keywords: Fibrinogen, fibrin, tissue plasminogen activator, plasminogen, conformational changes, synthetic peptide knobs
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Searching for Differences between Fibrinogen and Fibrin that Affect the Initiation of Fibrinolysis
Volume: 6 Issue: 3
Author(s): Russell F. Doolittle
Affiliation:
Keywords: Fibrinogen, fibrin, tissue plasminogen activator, plasminogen, conformational changes, synthetic peptide knobs
Abstract: Although in a gross sense fibrin is merely a collection of fibrinogen molecules packed together in bundles, numerous small structural differences can arise as a result of the conversion of the soluble precursor into the gelled product. Some of the consequences are obvious, others more subtle. In one way or another, all these changes are the result of a sequence of events that includes the release of the fibrinopeptides A and B, the formation of protofibrils, the cross-linking of γ chains, the assembly into mature fibers and the cross-linking of α chains. Numerous immunologic differences between fibrinogen and fibrin have been cataloged, and putative sites for fibrin enhancing the activity of plasminogen activators have been identified. Although some conformational changes have been found by X-ray crystallography, the structural changes leading to the exposure of sites thought to bind t-PA and/or plasminogen remain to be demonstrated.
Export Options
About this article
Cite this article as:
Doolittle F. Russell, Searching for Differences between Fibrinogen and Fibrin that Affect the Initiation of Fibrinolysis, Cardiovascular & Hematological Agents in Medicinal Chemistry 2008; 6 (3) . https://dx.doi.org/10.2174/187152508784871954
DOI https://dx.doi.org/10.2174/187152508784871954 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Progress Towards the Development of DHQO Derivatives and Related Analogues with Inotropic Effects
Mini-Reviews in Medicinal Chemistry Computer Aided Systems for Diabetic Retinopathy Detection Using Digital Fundus Images: A Survey
Current Medical Imaging Lipoprotein-associated Phospholipase A2 in Coronary Artery Disease
Current Topics in Medicinal Chemistry Hybrid Imaging: Conclusions and Perspectives
Current Medical Imaging Lipid Alterations in the Earliest Clinically Recognizable Stage of Alzheimers Disease: Implication of the Role of Lipids in the Pathogenesis of Alzheimers Disease
Current Alzheimer Research Potassium Channel Blockers and Openers as CNS Neurologic Therapeutic Agents
Recent Patents on CNS Drug Discovery (Discontinued) Use of Sulfated Fucans as Anticoagulant and Antithrombotic Agents: Future Perspectives
Current Pharmaceutical Design Ziziphi Spinosae Semen: A Natural Herb Resource for Treating Neurological Disorders
Current Topics in Medicinal Chemistry Extended Application of Digital Clock Drawing Test in the Evaluation of Alzheimer’s Disease Based on Artificial Intelligence and the Neural Basis
Current Alzheimer Research Perioperative Management of Female Hormone Medications
Current Clinical Pharmacology Solving the Blood-Brain Barrier Challenge for the Effective Treatment of HIV Replication in the Central Nervous System
Current Pharmaceutical Design Statins for the Prevention of First or Recurrent Stroke
Current Vascular Pharmacology Decreased Parathyroid Hormone Levels Despite Persistent Hypocalcemia in Patients with Kidney Failure Recovering from Septic Shock
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Biomarkers for Lupus Nephritis in the “OMICS” Era
Current Medicinal Chemistry What’s Age Got to do with it? A Review of Contemporary Revascularization in the Elderly
Current Cardiology Reviews Stress Response Regulation in Panic Disorder
Current Pharmaceutical Design Vascular Aging and Stroke
Current Medicinal Chemistry Stem Cell-Derived Motor Neurons: Applications and Challenges in Amyotrophic Lateral Sclerosis
Current Stem Cell Research & Therapy Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase: New Targets for Future Antidepressants
Current Neuropharmacology Lipid Metabolism in Patients with End-Stage Renal Disease: A Five Year Follow-up Study
Current Vascular Pharmacology